{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03832569","nct_id":"NCT03832569","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03832569. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.","label":"Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-02","type":"ESTIMATED"},"conditions":["Solid Tumors","Identified by NGS, PCR or IHC"],"enrollment":{"count":17,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-05","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Single-Arm Pilot Study of Adjuvant Pembrolizumab in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery","overall_status":"ACTIVE_NOT_RECRUITING","phases":["EARLY_PHASE1"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"proportion of patients with ctDNA clearance","timeFrame":"12 months post randomization"}],"references":[{"citation":"Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 May 15;128(10):1894-1899. doi: 10.1002/cncr.34140. Epub 2022 Feb 18. No abstract available.","pmid":"35179774","type":"DERIVED"},{"citation":"Mendonca Gorgulho C, Krishnamurthy A, Lanzi A, Galon J, Housseau F, Kaneno R, Lotze MT. Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. J Immunother. 2021 Feb-Mar 01;44(2):49-62. doi: 10.1097/CJI.0000000000000357.","pmid":"33416261","type":"DERIVED"}],"start_date":{"date":"2019-02-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03832569"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03832569"}